Saturday, August 2, 2025 8/2/2025

IN VIVO OCULAR ANGIOGENESIS ASSAY

Award Number: R43EY016254
ORGANIZATION: NATIONAL EYE INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/01/2005
PERIOD OF PERFORMANCE END DATE: 04/30/2006

Group Awards By:

View Award Description

IN VIVO OCULAR ANGIOGENESIS ASSAY - Eye diseases related to neovascularization are: diabetic retinopathy and age-related macular degeneration, the two leading causes of adult blindness in developed countries; retinopathy of prematurity, the major cause of vision loss in premature infants; and corneal neovascularization due to corneal injury, infection, or failed transplantation. Using zebrafish, this SBIR aims to develop a quantitative in vivo assay for assessing drug effects on ocular neovascularization. This SBIR will also investigate embryogenesis and patterning. Zebrafish is uniquely suitable for screening drugs that block ocular neovascularization. The pattern of vessels on the surface of the zebrafish eye is tightly regulated, permitting easy visual screening for drug effects. The transparency of the embryo permits identification of defects in vessel development in the eye and throughout the embryo. Rapid ex-utero development of the zebrafish allows drug administration, either by direct incubation in fish water (for small molecule) or injection (for large molecules such as RNA, DNA, morpholinos oligonucleotides, or antibodies). Zebrafish embryos do not require blood for normal development during the first week, obtaining sufficient oxygen by diffusion. Therefore, it is possible to perform treatment of the whole animal with anti-angiogenic drugs. The proposed zebrafish assay will facilitate development of therapeutic drugs to treat eye diseases caused by neoangiogenesis.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2005 ( Subtotal = $156,599 )
2005	2005	PHYLONIX PHARMACEUTICALS, INC	100 INMAN STREET SUITE 300	CAMBRIDGE	MA	02139	MIDDLESEX	USA	Vision Research	000	1	4/30/2005	NEW	$156,599
														Subtotal = $156,599

Grand Total All Awards = $156,599

Top

All Categories

About

Search

Reports

Data Submission

Award Information

IN VIVO OCULAR ANGIOGENESIS ASSAY

Award Number: R43EY016254

ORGANIZATION: NATIONAL EYE INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/01/2005

PERIOD OF PERFORMANCE END DATE: 04/30/2006

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer